Name:
Professor Jesmond Dalli FBPhS
Organisation:
Queen Mary, University of London
Year elected:
2023
Primary professional setting:
Academia
Dr Dalli graduated in 2009 with a PhD in Biochemical Pharmacology from Queen Mary University of London working with Professor Mauro Perretti exploring the biology and pharmacology of the pro-resolving protein Annexin A1. He then moved to Harvard Medical School and the Brigham and Women’ Hospital in Boston working with Charles Serhan on the structure elucidation of specialized pro-resolving mediators. Dr Dalli was awarded a Sir Henry Dale Fellowship and the ERF Young Investigator Award in 2017. He was promoted to Professor at Queen Mary University of London in 2019. Dr Dalli’s research interests focus on leveraging resolution mechanisms as novel therapeutic leads in the treatment of chronic inflammatory conditions. As part of his efforts in resolution pharmacology he developed peptides based on the Annexin A1 protein that display potent protective activities. One of these peptides is currently being evaluated in phased 2 clinical studies. Jesmond’s current efforts are focused on leveraging the biology of specialized pro-resolving mediators, molecules produced from omega-3 fatty acids, as biomarkers for patient stratification and leads in the development of novel therapeutics.